< Back to Schedule

Late-Breaking Abstract Session

Monday, November 16
2:00 pm
3:30 pm


No items found.

About the Session

Join this session to hear the latest scientific advances in hepatology. Presentations will be followed by a live moderated Q&A

  • The "Keep it Simple and Safe" Approach to HCV Treatment: Primary Outcomes from the ACTG A5360 (MINMON) Study Presenting Author Sunil Solomon
  • A Phase 2 Study of Peginterferon Lambda, Lonafarnib, and Ritonavir for 24 Weeks: End-Of-Study Results from the LIFT HDV Study Presenting Author Christopher Koh
  • HBV RNAi Inhibitor RG6346 in Phase 1b-2a Trial was Safe, Well-Tolerated, and Resulted in Substantial and Durable Reductions in Serum HBsAg Levels Presenting Author Man-Fung Yuen
  • A Multi-Site Randomized Pragmatic Trial of Patient-Centered Models of Hepatitis C Treatment for People Who Inject Drugs: The Hero Study Presenting Author Alain Harris Litwin
  • Enhance: Safety and Efficacy of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) - A Phase 3 International, Randomized, Placebo-Controlled Study Presenting Author Gideon Hirshfield
  • Results of Phase 2, Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis (EPICS) Presenting Author Raj Vuppalanchi